Active Ingredient(s):Glecaprevir + Pibrentasvir FDA Approved: * August 3, 2017 Pharm Company: *ABBVIE INC Category:Hepatitis
Glecaprevir/pibrentasvir (G/P), sold under the brand names Mavyret and Maviret, is a fixed-dose combination medication used to treat hepatitis C. It contains glecaprevir and pibrentasvir. It works against all six types of hepatitis C. At twelve weeks following treatment between 81% and 100% of people have no evidence of hepatitis C. It is taken once a day by mouth with food....
* May have multiple approval dates, manufacturers, or labelers. 3 Discussions